Related Experiment Videos
Endoglin (CD105) expression in endometrial carcinoma
Reda S Saad1, Katherine M Jasnosz, Ming Y Tung
1Department of Pathalogy, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA.
Summary
Endoglin (CD105) is a more sensitive marker for tumor angiogenesis in endometrial carcinoma than CD31. It also shows prognostic significance, correlating with invasion, metastasis, and tumor stage.
Area of Science:
- Oncology
- Pathology
- Biomarkers
Background:
- Tumor angiogenesis is crucial for endometrial carcinoma (EC) growth and metastasis.
- Identifying reliable markers for angiogenesis is vital for prognostic assessment.
Purpose of the Study:
- To evaluate endoglin (CD105) as an endothelial marker for angiogenesis in EC.
- To assess the prognostic significance of endoglin compared to CD31 and vascular endothelial growth factor (VEGF).
Main Methods:
- Immunohistochemical staining for endoglin, CD31, and VEGF in 55 EC, 10 complex endometrial hyperplasia with atypia (CHA), and 10 simple hyperplasia (SH) cases.
- Quantification of microvessels (MV) in hot spots and scoring of VEGF intensity.
- Statistical correlation with prognostic parameters.
Main Results:
- Endoglin staining revealed significantly more microvessels than CD31 (p < 0.001).
- Endoglin counts correlated significantly with tumor differentiation, invasion depth, angiolymphatic invasion, lymph node metastases, and tumor stage.
- VEGF expression correlated with angiolymphatic invasion and lymph node status.
- Endoglin and VEGF showed significant differences between CHA and SH (p < 0.001).
Conclusions:
- Endoglin is a more specific and sensitive marker for tumor angiogenesis in EC than CD31.
- Endoglin staining possesses prognostic value, correlating with key indicators of disease progression.